I. Introduction
I NSULIN-LIKE growth factor type I (IGF-I) resistance as a cause of short stature in human beings has not been widely recognized. With the wider applicability of techniques of molecular biology and a greater understanding of the components of the human "GH-IGF-I axis," new genetic abnormalities associated with growth retardation have been identified, involving the proximal portion of this axis, as well as IGF-I itself (1, 2) . Studying the clinical syndrome of IGF-I resistance has further contributed to the evolution of our knowledge regarding this complex system. This article reviews our current understanding of the GH-IGF-I axis and discusses animal models and human conditions associated with IGF-I resistance.
II. The IGFs and Their Receptors
The existence of IGFs (somatomedins) was first postulated in the 1950s when Salmon and Daughaday (3) demonstrated the existence of a GH-dependent sulfation factor. Concurrent research had identified nonsuppressible insulin-like activity in normal serum (NSILA) (4) . A third line of investigation described multiplication-stimulating activity (MSA), a mitogenic factor produced by fetal Buffalo rat liver cells that had the mitogenic and metabolic characteristics of sulfation factor and NSILA (5) . In the mid-1970s, two candidate somatomedins were purified (6, 7) . Later, they were shown to resemble proinsulin and were thus renamed insulin-like growth factors (IGFs) (8) .
IGF-I is a 70-amino acid peptide that has 50% sequence homology with insulin and 70% homology with IGF-II (8) . Both IGF-I and IGF-II are encoded by single large genes, IGF-I on the long arm of chromosome 12, and IGF-II on the short arm of chromosome 11. Like insulin, both IGFs have A and B chains that are linked by disulfide bonds. Although the liver is the major source of the IGFs, there is great variability of tissue expression at various stages of development.
Most of the actions of IGF-I and IGF-II are mediated by the type 1 IGF receptor (IGF1R). For a comprehensive review of the molecular and cellular biology of the IGF1R, the reader is referred to the 1995 Endocrine Reviews article by LeRoith et al. (9) . Like the insulin receptor, with which it has a high degree of homology, the IGF1R is a member of the tyrosinekinase class of cell-surface receptors (10) . It consists of two ␣␤-half-receptors, linked by disulfide bonds between the ␣-subunits to form the mature ␣ 2 ␤ 2 -heterotetrameric holoreceptor. The ␣-subunit, containing cysteine-rich regions, contains the site of IGF-I binding while the intracellular region of the ␤-subunit possesses tyrosine kinase activity. Multiple forms of the ␣-and ␤-subunits have been described in various tissues and cell lines, the etiology and functions of which are unclear (9) . The IGF1R binds insulin and IGF-II with 100-to 1000-fold and 2-to 15-fold lower affinity, respectively, than IGF-I.
The human IGF1R cDNA has been expressed (10) and the 5Ј-flanking region of the gene has been cloned and characterized (11) . There are several atypical features, including an unusually long 5Ј-untranslated region (Ͼ1 kb from the ATG). With a numbering system starting with the transcription start site designated "0," the putative promoter region is Ϫ1 to Ϫ517. The sequence is 72% GC-rich and lacks identifiable TATA and CAAT boxes. There is an initiator motif at Ϫ6 to ϩ11, which contains the single transcription start site. There is also a consensus sequence for the transcription factor AP-2 and five sites for Sp1 (GC boxes), as well as a sequence that is weakly homologous to the binding site of an epidermal growth factor (EGF) receptor transcription factor. Deletion analysis of the promoter and upstream region indicates that a HindII-SstI fragment (Ϫ517 to ϩ439) has significant promoter activity (11) . Studies of the rat IGF1R promoter demonstrate that Sp1, a ubiquitous member of the family of zinc-finger transcription factors, can regulate expression of the IGF1R gene by acting both on GC boxes in the 5Ј-flanking region of the promoter and on a CT element (a homopurine/ homopyrimidine motif) in the 5Ј-untranslated region (12) . Mutations or deletions of the promoter sequence could result in reduced IGF1R gene expression. Nonsense mutations or stop codons in the coding sequence could result in decreased IGF1R numbers. These alterations in gene structure could diminish the binding of IGF-I to its receptor, thereby causing IGF-I resistance.
Upon ligand binding, the receptor autophosphorylates and initiates a series of cytoplasmic kinase activations which, in turn, activate nuclear transcription factors. A defect in IGF-I action would result if proper ligand binding did not occur. This could happen if either IGF-I or the IGF-1R were altered (as in the case of a mutation in the coding sequence or if autoantibodies against either component interfered with normal binding). As a result of the close homology between IGF-I and insulin receptors, there is formation of hybrid insulin/IGF-I receptors. Such hybrids have been isolated from various tissues and cultured cell lines and may be common in vivo (9) . These hybrids bind both IGF-I and insulin with affinities comparable to pure IGF1R (13, 14) . Although the IGF-I half-receptor can bind ligand, dimerization is necessary for trans-autophosphorylation and cellular response. Thus, the presence of kinase-defective insulin receptors could result in relative IGF-I resistance, especially if an increased number of defective insulin receptors compete with normal IGF1Rs for dimerization.
IGF1R action involves components of several intracellular signaling pathways (9) . Ligand binding induces IGF1R autophosphorylation, resulting in activation of intrinsic tyrosine-kinase activity. The predominant substrate of IGF1R is the insulin receptor substrate-1 (IRS-1), a "docking" protein that can bring together and regulate the activity of some intracellular proteins (15) . IRS-1 activates Ras via a Grb2-mSos signaling pathway. Ras, in turn, activates a cascade of protein kinases leading to mitogen-activated protein (MAP) kinase (16, 17) . MAP kinases can regulate a variety of cellular and nuclear proteins, including transcription factors. IRS-1 also interacts with Grb-S, Nck, and Syp, which are other proteins involved in growth-factor signaling pathways (9) . The phosphorylation cascade activated by the IGF1R tyrosine kinase also activates Shc, which associates with Grb2 and subsequently activates Ras. Other less well characterized substrates of the IGF1R include a cytoskeletal protein, other MAP kinases, and some nuclear protein products such as c-jun. These may be direct or indirect targets. IGF-I signaling may be negatively modulated by the protein kinase A signaling pathway and by CD45 phosphotyrosine phosphatase. Disruption of an intracellular second-messenger pathway (i.e., by a mutation of the gene encoding a key component) could result in resistance to IGF-I and other growth factors whose receptors share the pathway for signal transduction. Alternatively, resistance to a hormone that competes for shared second messengers could cause secondary IGF-I resistance by shunting away necessary intermediaries.
The type 2 IGF receptor has no structural homology to the IGF1R or the insulin receptor. However, it is identical to the cation-independent mannose-6-phosphate receptor and is thus referred to as the IGF-II/Man-6-P receptor (18) . The human IGF-II/Man-6-P receptor gene is located on chromosome 12 (19) and encodes a single peptide chain (18) . The receptor has different binding sites for IGF-II and Man-6-P or Man-6-P-containing glycoproteins. The receptor does not have tyrosine kinase activity. As yet, the mechanism of signal transduction has not been elucidated. The IGF-II/Man-6-P receptor also binds IGF-I with lesser affinity.
In plasma, IGFs are complexed with binding proteins (IGFBPs) that extend their serum half-life, transport them to target cells, and modulate their interactions with membrane receptors (20 -22) . Six IGFBP cDNAs have been cloned and sequenced (21, 22 ) with a seventh currently being characterized (23) . They have significant sequence homology (24) . IGFBP-3 is the primary serum IGFBP and is associated with a supporting protein, acid-labile subunit. Multiple studies have shown IGFBP-3 levels to be GH-dependent (25, 26) . One study using transgenic mice supported IGFBP-3 being IGF-I-dependent (27) . Mice that were GH deficient had a 15.7-fold decrease in serum IGF-I and a 5.5-fold decrease in serum IGFBP-3, whereas those GH-deficient mice that expressed IGF-I had serum levels of IGF-I and IGFBP-3 that were 69% and 64% of those in normal sera, respectively. In mice with IGF-I overexpression, serum IGFBP-3 was increased 2.9-fold. There continues to be debate as to whether IGFBP-3 is IGF-I-dependent in humans. Gargosky et al. (28) have described GH-receptor-deficient adults who have high GH levels, and low IGF-I, IGF-II, and IGFBP-3 levels. Administration of IGF-I to these patients failed to increase IGFBP-3 levels. It is not clear whether this finding can be generalized to normal human subjects.
True to the somatomedin hypothesis, most of the actions of GH are mediated by IGF peptides. Circulating GH stimulates hepatic IGF-I production, which is reflected in serum IGF-I levels. In a variety of tissues, there is also IGF-I production that may have autocrine and paracrine effects. Although GH and the IGFs also have a variety of actions that are independent of each other, the relative roles of GH and IGF-I are not completely understood. Although both IGF-I and GH stimulate growth and protein synthesis, the quantitative growth effect of GH is greater with differential effects on various organs (29) . The metabolic effects of GH and IGF-I also differ somewhat in that the former is "diabetogenic" and the latter has blood glucose-lowering effects. IGF-I action in vitro includes effects on cell-cycle progression, proliferation, death, differentiation, and a variety of cell-specific functions (1).
III. Genetically Engineered Mouse Models
The development of embryonic stem cell technology has allowed investigators to study the effects of targeted removal of one or more genes from an animal. Mouse "knockout" studies have led to a greater understanding of the pre-and postnatal effects of IGF-I, IGF-II, and the IGF1R on growth and development. The IGF1R-deficient mouse provides a model of primary IGF-I resistance. Animals with this mutation, in conjunction with IGF-I or IGF-II gene deletion, allow further investigation into the interactions between IGFs and the IGF1R.
There are various strategies of gene targeting that involve homologous recombination between an introduced mutated gene and an endogenous chromosomal allele. Replacement vectors are constructed using subcloned genomic fragments of the gene of interest and transcriptionally competent neo and tk casettes (30, 31) . The casettes replace critical coding regions of the gene and either produce multiple stop codons or abolish function of the protein product. Embryonic stem cells are transfected by electroporation and selected by single or double antibiotic resistance before they are expanded. After DNA analysis to identify clones with homologous recombination, approximately five to 15 clones are injected into blastocysts, and the embryos are replanted into pseudopregnant female mice. Chimeric animals that incorporated the embryonic stem cells into their germline transmit the mutant DNA to their offspring. Heterozygotes are then inbred to yield animals homozygous for the disrupted gene.
Animals that were heterozygous for the IGF1R mutation [IGF1R(Ϫ/Ϫ)] had no discernible difference in phenotype from wild-type animals (32) . Those animals with complete absence of the IGF1R [IGF1R(Ϫ/Ϫ)] were significantly smaller at birth than were wild-type animals (32) (33) (34) (35) . This is in contrast to the observation that absence of GH in mutant animals or experimental ablation of the pituitary gland does not affect prenatal growth (36 -39) . Finally, the IGF1R(Ϫ/Ϫ) mice had severe growth retardation with approximately 45% of normal birth weight and had 100% neonatal mortality (32) . The pups were born alive and made visible efforts to breathe but become cyanotic and died in a few minutes. Apparently, air never reached the alveoli, although histopathological examination revealed no particular abnormalities. There were no structural blockages, no abnormality of the alveolar epithelium, and no difference in immunostaining for surfactant apoprotein compared with wild-type animals. There was, however, significant generalized hypoplasia of all tissues, including respiratory muscles, which may explain the respiratory failure at birth. The skin was translucent with abnormally thin stratum spinosum. Examination of the nervous system revealed significantly increased cellular density in the mantle zone, thought to be secondary to a reduction in the surrounding neuropil (i.e., neuronal fibers and cytoplasm of neuroglial cells). The timing of the first appearance of several ossification centers was analyzed with the finding that IGF1R(Ϫ/Ϫ) animals had a delay of 2-4 embryonic days in development of ossification centers of cranial and facial bones.
Studies of double-mutant animals have provided further insight into the interaction of IGFs with IGF1R (32). The In summary, the major conclusion from studying animals with absence of IGF1R is that the IGFs, independent of GH, are essential for normal embryonic growth and possibly development in mice. The second significant conclusion from the study of IGF1R-deficient mice is that the IGF1R gene is an essential gene in mice. Viability of the IGF-II(p-) strains suggests that the critical element necessary for life in those animals is the interaction between IGF-I and the IGF1R. IGF-I interacts primarily with the IGF1R, but may also have in vivo interactions with insulin/IGF-I hybrid receptors. The variable survival of the animals with absence of IGF-I [IGF-I(Ϫ/Ϫ)] [5-68% vs. the 100% mortality seen with IGF1R(Ϫ/Ϫ)] indicates the presence of compensatory mechanisms, perhaps involving the action of IGF-II through the IGF1R.
IV. Malnutrition
Significant and prolonged malnutrition is characterized by diminished weight gain and impaired linear growth. Although the exact mechanism for the growth failure associated with malnutrition is unknown, roles for GH resistance, IGF-I deficiency, and IGF-I resistance have been promulgated based mostly on data derived from experiments performed on protein-restricted rats (40) .
In studies of Sprague-Dawley rats either fasted for 3 days or fed a reduced protein diet, GH receptor and IGF-I mRNA levels were coordinately decreased in liver (41) . Other studies of protein-restricted animals suggested maintenance of normal GH-receptor function with the emergence of a post-GH-receptor defect. In fasting rats, serum GH and IGF-I levels fall (42) , whereas there are normal or increased serum GH and reduced IGF-I levels in human fasting, kwashiorkor, and marasmus (40) . The reduced serum IGF-I levels reproducibly found in states of chronic human undernutrition have been linked to concomitant GH resistance (40) , reduced amino acid availability (43) , alterations in IGFBPs (increased IGFBP-1 and -2) (44), and enhanced serum clearance and degradation of IGF-I (40).
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IGF-I RESISTANCEInitial studies of protein restriction in rats demonstrated a state of apparent GH resistance (45) . The low serum IGF-I levels that ensued were not restored to normal after physiological GH replacement, which successfully normalized IGF-I levels in hypophysectomized rats. Moreover, these physiological GH doses, as well as a regimen of supraphysiological GH replacement that increased serum IGF-I levels 2-fold over baseline (but to levels still ϳ50% of rats fed a normal protein diet), both failed to promote growth. Since IGF-I deficiency is readily apparent after 12 h of protein restriction, at which time there are only minimal effects upon GH receptors, the induced GH resistance is thought to be postreceptor in origin (46) . The specific mediator of this phenomenon is unknown. One proposed mechanism involves the effects of amino acid restriction on hepatic protein synthesis, as reflected by a specific reduction in IGF-I mRNA synthesis (43) .
The above studies suggest that insufficient dietary protein may block the actions of IGF-I in addition to those of GH. To test this hypothesis, Philipps et al. (47) administered recombinant IGF-I to neonatal rats who were intentionally malnourished by increasing litter size. After body weight reductions of 20 -25%, IGF-I injections failed to stimulate any increase in somatic growth of these animals (47) . Similar experiments were conducted by Thissen et al. (42) in which 4-week-old protein-restricted rats were infused with recombinant IGF-I for 1 week. Although this treatment regimen normalized serum IGF-I concentrations, carcass growth was not stimulated. Of note, the infusion of IGF-I into well nourished hypophysectomized rats at a 50% lower dose induced a significant increase in carcass growth. Furthermore, combined infusion of GH and IGF-I also failed to stimulate significant carcass growth (40) . Analogous studies in obese humans subjected to dietary restriction and GH treatment for 11 weeks showed loss of an initially observed augmentation of nitrogen balance despite maintenance of persistent elevations in plasma IGF-I concentrations (48) . The authors of this latter study concluded that the loss of the anabolic action of GH under these conditions may have resulted from the development of IGF-I resistance.
Taken collectively, the above observations indicate that protein malnutrition is associated with combined GH and IGF-I resistance. In addition, serum IGF-I levels are low despite IGF-I resistance. This apparent paradox may arise directly from coexisting GH resistance or result from the ability of undernutrition to override an increased serum IGF-I level, which might be predicted based on standard negative feedback, as usually occurs with ligand in the setting of reduced receptor activity and/or reduced downstream postreceptor function.
V. Conditions Associated with Genetic IGF-I Resistance in Humans

A. African Efe Pygmies
The African Pygmies are a unique population of shortstatured humans whose existence dates back to early Paleolithic times. Their stunted height should be thought of as a variation (or adaptation), rather than as a defect or abnormality, since being small is likely to be the result of an evolutionary adaptation for such populations, which have experienced, perhaps for thousands of years, cyclical undernutrition (i.e., subsisting in a hot, humid rain forest with low-lying, dense vegetation), and have not received significant gene flow from other populations (49 -51) . Early studies of Mbuti and Babinga Pygmies concluded that their prepubertal growth was similar to that of other Africans and that their short adult stature was due primarily, if not solely, to absence of an adolescent growth spurt (52) (53) (54) . These studies, however, were carried out on subjects of estimated age and employed cross-sectional data. More recent investigations in which African Pygmy children from the Efe tribe of nomadic hunter-gatherers in northeast Zaire were followed from birth longitudinally to 5 yr of age noted that the growth retardation of Pygmy children is present at birth and, during the first 5 yr of life, becomes progressively greater (55, 56) . The Efe children show a trend of increasingly negative mean sd score compared with an American reference population, from Ϫ2.71 (sd ϭ 0.93) at 6 months to Ϫ4.16 (sd ϭ 0.46) at age 5 yr and Efe children's stature declines steadily in comparison to other African rural populations (56) . The resultant mean adult stature of male Efe Pygmies (143 cm) is the shortest of any human population known, including other Pygmy populations of Africa (55) .
The exact mechanism of short stature in African Pygmies is unknown although early evidence implicated resistance to the growth-promoting action of GH as the cause (57) on the basis of 1) low serum IGF-I levels in adult Pygmies (58); 2) failure of short-term GH administration in the field to Pygmies to induce the expected rise in serum IGF-I levels, nitrogen retention, increased insulin secretion, increased urinary excretion of calcium, and decreased urinary excretion of phosphate (59); 3) reduced secretion of IGF-I by EpsteinBarr-virus (EBV)-transformed B lymphocyte cell lines established from six adult African Pygmies in response to in vitro GH stimulation compared with that secreted by control cell lines (60); 4) low serum levels of high-affinity GHBP (61, 62) , a fragment of the extracellular portion of the GH receptor which is presumed to be proportionate to the number of functioning tissue-bound GH receptors in Pygmies (63); and 5) a restriction fragment length polymorphism present in 0.17-0.33% of GH receptor genes in two Pygmy populations, but present in only 0.02% of nonPygmy Africans (57) .
Despite these observations leading to the notion that GH resistance was the underlying mechanism responsible for the short stature of the African Pygmy, it should be noted that African Pygmies bear no particular morphological or biochemical resemblance to individuals with genetically mediated GH resistance due to proven mutations in the GH receptor gene, i.e., Laron dwarfs (64), other than that both groups are very short. It seemed reasonable, therefore, to explore other mechanisms for Pygmy short stature, specifically IGF-I resistance, since GH resistance, at least in theory, could be an epiphenomenon resulting from underlying IGF-I resistance (65) . At the same time, it became important to find alternative explanations for the aforementioned evidence linking GH resistance to stunted Pygmy growth that would also be consistent with our own hypothesis. For example, failure of short-term GH treatment to induce expected met- (61, 62) suggested that these subjects have at least a partial deficiency of GH receptors (63), it is possible that unintended inaccuracies in estimating age (56, 66) and nutritional repletion account for observed differences in serum GHBP levels between Pygmies and controls. Furthermore, there is significant overlap between GHBP levels in Pygmies and controls (62) . Despite the disproportionate representation of the aforementioned restriction fragment length polymorphism in the GH-receptor gene in Pygmies (57), more recent studies have found a normal sequence of the GH receptor gene, including its 3Ј-and 5Ј-extensions, in these Pygmies (62) .
With the development of HTLV T lymphocyte and EBV B lymphocyte immortalization technologies, we have been able to acquire hormonally responsive cell populations that reflect the genetic complement of the individuals from whom they arose. This technology has demonstrated fidelity insofar as detection of genetically mediated resistance to GH in four patients with Laron dwarfism and to insulin in a patient with leprechaunism (67, 68) . We thus sought to establish cell lines from Efe Pygmies as a means to confirm or refute the presence of GH resistance and also to quantify responsiveness to IGF-I. From two separate expeditions to Zaire, we were able to establish eight T-and three B cell lines from adult Efe Pygmies as well as three T cell lines from neighboring Lese farmers. It should be pointed out that there is known admixture between the Lese farmers and Efe Pygmies, which leads to maternal transmission of Efe genes into the Lese gene pool (69) and that the heights of the Lese are intermediate between those of the Efe and urban black Africans.
With this background, we performed in vitro clonal proliferation (clonogenic) assays in which T cell lines (70, 71) from Pygmy, Lese, and American controls were incubated with recombinant human IGF-I (in a concentration range of 7-250 ng/ml); recombinant human GH (25-500 ng/ml); recombinant human insulin (7-250 ng/ml); or PBS at pH 7.4. After 7-10 days, T cell colonies containing a minimum of eight cells were enumerated using an inverted microscope. For studies with B cell lines (72) , proliferative responses of Pygmy and control cell lines were compared after stimulation with recombinant human IGF-I (5-250 ng/ml); the phorbol ester, phorbol 12-myristate 13-acetate (10 -100 nmol/liter); or PBS at pH 7.4. After 4 -7 days, B cell colonies containing a minimum of seven cells were counted.
In these studies (70, 71) , T cell lines from eight Efe Pygmies were found to be completely resistant to the growth-promoting actions of IGF-I concentrations as high as 250 ng/ml and GH concentrations as high as 500 ng/ml, whereas control cell lines demonstrated a typical bimodal response to IGF-I (Fig. 1A) and unimodal response to GH (Fig. 1B) . Interestingly, T cell lines from neighboring Lese farmers responded to both IGF-I and GH in an intermediate manner with respect to the Pygmies and American controls, consistent with their aforementioned genetic admixture. Further- 
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IGF-I RESISTANCEMean overall response profiles of T cell lines to insulin were no different among Pygmies, Lese, and American control subjects (Fig. 1C) . The lack of a blunted response of Pygmy T cell lines to the higher insulin concentrations was somewhat unexpected since we previously showed that the action of insulin at concentrations greater than 10 ng/ml in our clonal system was mediated through the IGF1R (67, 73) . To explain this apparent inconsistency in our theory that Efe Pygmies are resistant to IGF-I, it should be noted that the responsiveness of our first Pygmy T cell line to insulin concentrations greater than 10 ng/ml, unlike that of American control T cell lines, was not mediated through the IGF1R since it was not significantly blocked by preincubation with ␣IR-3 monoclonal antibody against the IGF1R (70). Another possible explanation for this apparent paradox is that there is formation of chimeric, functional insulin-IGF-I receptors (74) by the Pygmy T cell lines that retain responsiveness to insulin, but not to IGF-I.
To expand upon our finding of IGF-I resistance, we next chose to verify that this unique finding was present in a second tissue, namely, B lymphocytes (72) . Indeed, the Efe B cell lines showed essentially no responsiveness to the entire IGF-I concentration range, whereas control B cell lines demonstrated a typical bimodal stimulation of ϳ50% above baseline for each peak (Fig. 2) . In contrast, Pygmy and control B cell lines responded with comparable stimulation to all concentrations of phorbol 12-myristate 13-acetate, a phorbol ester which does not activate the IGF1R (75), thus confirming the specificity of the observed resistance to IGF-I.
In the setting of IGF-I resistance, it might be expected that serum IGF-I levels would be elevated if classical negative feedback regulation were operative. In fact, in our studies (not controlled for nutritional status) of adult male Efe Pygmies (70, 71) , serum IGF-I concentrations were actually low in five Pygmies and within the normal range for American controls in two others. In previous studies of Pygmies, IGF-I levels have either been low or normal depending on the degree and certainty of nutritional repletion and on the presence or absence of concomitant infection (52, 76) . Failure to detect elevated total serum IGF-I concentrations in Pygmies in the face of IGF-I resistance could reflect concomitant protein malnutrition which lowers serum IGF-I levels (77) , as occurs in the experimental protein-malnourished rat model (45, 42) . Furthermore, no abnormalities of IGF-I allelic distribution in Pygmies vs. African controls or of the Pygmy IGF-I gene sequence have been found (78) . In comparison, despite the long-held tenet that the short stature of African Pygmies is the result of GH resistance, elevated serum GH levels have not been previously reported (79) . In our Pygmy subjects, random GH levels were detectable in all subjects, and slightly elevated in two individuals (70, 71) . Of note, elevated GH levels typically occur in the setting of protein malnutrition (80) . In addition, in our study, IGF-II levels were low in five of seven Pygmies, IGFBP-3 levels were low in three and normal in four Pygmies, and GHBP levels were low in six and normal in one Pygmy (71) . For comparative purposes, hormonal analyses in another short-statured population, the Mountain Ok people of the highlands of Papua, New Guinea (average adult male height 151 cm) reveal normal levels of GH, IGF-I, IGF-II, but low levels of GHBP (81) .
We next undertook three additional sets of experiments to expand upon our observation of IGF-I resistance in Pygmy tissues. Our first approach centered around the ability of GH to induce resistance to the in vitro growth-promoting action of insulin. Accordingly, we performed studies in which American control, Lese, and Pygmy T cell lines were stimulated with insulin alone and after preincubation with either GH or IGF-I (82). Preincubation with GH induced subsequent resistance to the mitogenic action of insulin with T cell lines from multiple American controls (Fig. 3A) and an African Lese (Fig. 3B ), but failed to reduce the proliferative response of a Pygmy T cell line after insulin stimulation (Fig.  3C) . A similar pattern of response to insulin of each group was found after IGF-I preincubation (Fig. 4, A-C) . Furthermore, the ability of either GH (Fig. 5A ) or IGF-I (Fig. 5B) to induce insulin resistance in American control and Lese T cell lines was completely abrogated by preincubation with ␣IR-3 antibody against the IGF1R. These observations suggest that the mechanism of GH-induced resistance to the mitogenic action of insulin is mediated by IGF-I in T cell lines of normal subjects, and that failure of either GH or IGF-I to induce insulin resistance in the Pygmy cell line is due to its inability to respond to IGF-I. This interpretation is consistent with in vivo studies showing that resistance to the metabolic action of insulin in acromegaly is more closely correlated to circulating IGF-I than to GH levels (83) .
Our second set of experiments capitalized upon the observation that the hormones, PTH, ACTH, and TSH, in addition to their respective actions on calcium and phosphate metabolism, cortisol production, and thyroid hormone synthesis, are also growth factors exerting trophic growth-promoting actions on bone, adrenocortical, and thyroid target tissues, respectively. In each case, available evidence suggests that this growth promotion is mediated by IGFs acting either alone or synergistically with the specific trophic hormone (84) . Thus, we undertook to clarify the role of IGF-I as to study the effects of PTH, ACTH, and TSH is supported by the presence of receptors for each of the hormones on normal lymphocytes (86 -88) . We also examined, using physiological and supraphysiological concentrations of PTH, ACTH, and TSH, the clonal responsiveness of a T cell line established October, 1998 IGF-I RESISTANCEfrom an Efe Pygmy with the hypothesis that there would be lack of response to each hormone if its growth-promoting effect requires the local action of IGF-I. Using this T cell model, we showed that the growth-promoting actions of these three growth factors upon normal T cells were completely blocked by pretreatment with ␣IR-3. Furthermore, there was no responsiveness of a Pygmy T cell line to either PTH, ACTH, or TSH, thereby confirming that the growthpromoting actions of these three hormones, which bind to cell-surface receptors, are, in each case, mediated by local IGF-I action, and, providing further evidence that Pygmy tissues are resistant to IGF-I. Our third set of validation experiments involved the quantification of T cell line proliferation in response to estradiol, testosterone, 1,25-(OH) 2 -vitamin D 3 , and T 3 (89) . We chose these representative steroid and thyroid hormones without certainty as to whether their growth-promoting actions upon T cells were mediated by local IGF-I production. We quantified colony formation of American control T cell lines in the presence and absence of ␣IR-3 and Pygmy T cell lines in response to physiological and supraphysiological concentrations of estradiol, testosterone, 1,25-(OH) 2 -vitamin D 3 , and T 3 . There were no statistically significant differences in response curves for any of the four hormones comparing control clonal responses in the presence or absence of ␣IR-3, and no statistically significant difference in responsiveness between control and Pygmy T cell lines. From these data, we conclude that 1) normal T cell lines proliferate in response to estradiol, testosterone, 1,25-(OH) 2 -vitamin D 3 , and T 3 , hormones that bind to cytoplasmic/nuclear receptors; 2) these responses are not mediated through local IGF-I since they are not blocked by pretreatment with antibody to the IGF1R; and 3) Pygmy T cell lines, which are genetically resistant to IGF-I, grow equivalently to control T cell lines in response to estradiol, testosterone, 1,25-(OH) 2 -vitamin D 3 , and T 3 , as would be predicted, since the growth-promoting actions of these hormones are IGF-I-independent in our system. Armed with the above information pointing toward IGF-I resistance as the basis for short stature in the Efe Pygmy, we next undertook experiments to determine the molecular basis for our observation of reduced in vitro clonal responsiveness of T cell lines to IGF-I (90). In so doing, we found markedly decreased cell-surface expression of IGF1Rs on T cell lines established from Efe Pygmies (confirmed by affinity cross-linking) (Fig. 6) , with normal IGF-I binding affinity compared with controls. Furthermore, the Pygmy IGF1Rs were not autophosphorylated in an in vitro kinase assay (Fig. 7) . In addition, in response to stimulation by physiological concentrations of IGF-I, the Pygmy IGF1Rs did not transmit downstream signals, as measured by protein tyrosine phosphorylation quantified by Western blot analysis and inducibility (above baseline) of the early response genes, c-jun and c-fos, quantified by Northern blot analysis (Fig. 8) .
On Northern blotting, there was a significantly reduced (2-13% of control) steady-state level of IGF1R mRNA (Fig. 9) . This represents decreased production of the mRNA since, in an RNase protection assay, there was equivalent stability of the IGF1R transcripts from Pygmy and American control cells after actinomycin D treatment. The nucleotide sequence of the full-length IGF1R cDNA in one Pygmy subject showed no significant variation from normal. Overall, four polymorphisms were found in Pygmy cDNA, although none were found in cDNA from all Pygmy subjects and not in control cDNA. Thus, no reproducible genetic alteration in the proteincoding sequence of the IGF1R was detected. In summary, we provide multiple lines of evidence that immortalized lymphocytes from African Efe Pygmies are resistant to the in vitro growth-promoting action of IGF-I directly and to hormones whose growth-promoting actions are mediated by local IGF-I. We have also found a molecular variation that we believe is associated with this reduced responsiveness to IGF-I, i.e., a reduced number of steadystate IGF1R transcripts and receptor sites, and a diminution in receptor phosphorylation and intracellular signaling. We suggest that these variations are related to the short stature of the Efe Pygmy.
B. Leprechaunism and other genetic disorders associated with severe insulin resistance
In 1948, Donohue (91) described a child born to a related couple who appears to be the first reported patient with leprechaunism. In 1954, with Uchida, Donohue described a sibling of the index case; both children manifested intrauterine and postnatal growth retardation; generalized lipodystrophy; facial hirsutism; and an aged face with thickened lips, large wide-set eyes, and large low-set ears (91, 92) . Beginning in the 1970s, additional clinical features of this syndrome, dubbed leprechaunism or Donohue syndrome, were described, including hyperinsulinemia, severe insulin resistance, and abnormal glucose homeostasis; acanthosis nigricans; clitoromegaly and ovarian hyperandrogenism in females; gonadotropin-independent precocious puberty; and myocardial hypertrophy (67, 93, 94) . The condition is inherited in an autosomal recessive fashion, affects approximately one in 4 million live births, and is usually associated with death in the first year of life (95, 96) .
In the late 1970s, studies of cultured fibroblasts from a child with leprechaunism showed markedly decreased insulin binding to insulin receptors and a severe reduction in the ability of insulin to stimulate glucose incorporation into the patient's cells (97) . This led to the suspicion that abnormalities in the insulin receptor might be responsible for this syndrome. Since the cloning of the human insulin receptor cDNA in 1985 (98, 99) , more than 50 various mutations in the insulin-receptor gene (typically either homozygotes or compound heterozygotes) have now been described. These mutations can be stratified into five subgroups resulting in either 
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IGF-I RESISTANCEdecreased levels of insulin-receptor mRNA, impairment of intracellular transport and posttranslational processing, defects in insulin binding, impairment of receptor-associated tyrosine-kinase activity, or accelerated insulin-receptor degradation (100). The frequent occurrence of acanthosis nigricans, ovarian hyperandrogenism in females, and myocardial hypertrophy in infants with leprechaunism led to the hypothesis that the massive hyperinsulinemia resulting from the underlying genetically mediated insulin resistance results in certain tissuespecific mitogenic effects mediated through a presumably intact homologous IGF1R-effector mechanism (93). The available data in leprechaun tissues are contradictory as to the normalcy of the IGF-I signaling pathway. The presence of normal IGF-I-mediated functions was first supported by in vitro observations in leprechaun Winnipeg/ NIH. In fibroblasts from this subject, IGF1R affinity was reduced by 75% compared with that seen in control fibroblasts. This defect was associated with reduced MSA-induced glucose incorporation, whereas MSA-stimulated methyl aminoisobutyric acid (AIB) uptake was normal (101). Rechler concluded that leprechaun Winnipeg/NIH possesses a defect in a component of the insulin receptor-effector mechanism that is common both the insulin receptor and the IGF1R, and that this abnormality is specifically involved in coupling both receptors to glucose incorporation, but is spared in their coupling to methyl-AIB uptake. In fibroblasts from another leprechaun patient, Sasaoka et al. (102) found reduced insulin binding and normal IGF-I binding, normal responsiveness of glucose incorporation and AIB uptake to insulin with a shift to the right in the dose-response curve (decreased sensitivity), and normal responsiveness and sensitivity of glucose incorporation and AIB uptake after IGF-I stimulation. These investigators reported similar findings in a 23-yr-old patient with the Kahn type A syndrome of insulin resistance, which usually occurs in young females in association with signs of virilization or accelerated growth (103) . In fibroblasts from leprechaun Minn-1 with a non-sense mutation in one of two insulin-receptor alleles at exon 14, mRNA levels for the insulin receptor were markedly decreased whereas IGF-I binding, and IGF1R gene mRNA content and transcription rate, were normal (104) .
In studies from our laboratory employing an HTLV-IItransformed T lymphoblast cell line from another infant with leprechaunism, we showed absent in vitro colony proliferation in response to physiological concentrations of insulin, but normal colony proliferation in response to supraphysiological concentrations of insulin and physiological concentrations of IGF-I (67). We deduced that these responses were mediated through an intact IGF1R-effector mechanism, based on studies employing ␣IR-3, a monoclonal antibody directed against the IGF1R (67) . More recent studies of fibroblasts from leprechaun Richmond reported by Jospe et al. (105) showed a non-sense mutation in the extracellular domain of the insulin-receptor gene resulting in the complete absence of cell-surface insulin receptors. However, both supraphysiological concentrations of insulin and physiological concentrations of IGF-I stimulated DNA synthesis normally in fibroblasts, an effect, in both cases, mediated through an intact IGF1R-effector mechanism, based on studies employing ␣IR-3 (105, 106). Normal IGF-I-induced hexose uptake into fibroblasts of a Dutch patient with leprechaunism has also been described despite a homozygous mutation in the ␣-chain of the insulin receptor and markedly reduced 2-deoxyglucose uptake by the patient's fibroblasts (107) . In a patient with leprechaunism from Japan with a homozygous mis-sense mutation in the tyrosine kinase domain of the insulin-receptor gene, there was a marked diminution in glucose uptake, IRS-1 tyrosine phosphorylation, thymidine incorporation into DNA, and glycogen synthase activation in response to insulin, yet glucose uptake and IRS-1 tyrosine phosphorylation were normal in response to IGF-I (108).
Thus, this leprechaun patient provides further evidence for preservation of a normal IGF1R-effector mechanism in the setting of a major genetic abnormality involving homologous insulin receptors.
The presence of dual defects in insulin and IGF-I action, as well as in EGF action (109, 110) , has been suggested as causative in the severe pre-and postnatal growth failure that affects all infants with leprechaunism. Moreover, Kaplowitz and D'Ercole (109) reported that stimulation of [ 3 H]AIB uptake by fibroblasts from a patient with leprechaunism in response to insulin, EGF, MSA, and somatomedin-C was uniformly decreased. In addition, these investigators demonstrated subnormal stimulation of [ 3 H]thymidine incorporation by the leprechaun fibroblasts in response to EGF, somatomedin-C, and fibroblast growth factor. Desbois-Mouthon et al. (111) described a leprechaun patient with severe resistance to both insulin and IGF-I. This patient had two mis-sense mutations located in the gene encoding the ␤-subunit of the insulin receptor. Mutant insulin receptors from this patient showed normal insulin binding, but elevated levels of in vivo autophosphorylation and in vitro exogenous tyrosine kinase activity in the absence of insulin, and no further stimulation with the addition of insulin. Moreover, these insulin receptors were unable to promote stimulation of either metabolic or mitogenic pathways. Although IGF-I binding and IGF-I-stimulated receptor kinase activity were normal, the ability of IGF-I to stimulate glycogen and DNA synthesis was significantly diminished compared with that seen in control fibroblasts. In a patient with the type A syndrome of insulin resistance and no discernible alteration in splicing or primary insulin-receptor structure, Knebel et al. (112) reported abnormal insulin binding due to reduced receptor affinity for insulin, abnormal metabolic and mitogenic responsiveness to insulin, and markedly impaired inducibility of c-fos mRNA in response to both insulin and IGF-I.
Another approach toward documenting the presence or absence of IGF-I resistance in states of genetically mediated insulin resistance is to study the in vivo effects of IGF-I administration to affected individuals. In a series of 11 patients from Japan with extreme insulin resistance, including patients with type A insulin resistance, congenital generalized lipodystrophy, and leprechaunism, short-term IGF-I treatment resulted in a fall in blood glucose in each patient to a degree comparable to that seen in normal individuals (113) . This hypoglycemic action was maintained for as long as 6 months. Similar partial beneficial metabolic effects in response to IGF-I administration were reported in two Swiss patients over a 10-day period (114) and in another Japanese patient for up to 9 months (115), both of whom had the type A syndrome of insulin resistance. In contrast, IGF-I treatment of two infants with leprechaunism failed to stimulate any apparent glucose-lowering or nitrogen-sparing effects (116) . Lastly, neither GH nor IGF-I administration to a child with the Rabson-Mendenhall syndrome (characterized by severe insulin resistance, abnormal glucose tolerance, typical coarse facial features, marked growth retardation, advanced dentition, abdominal protuberance, acanthosis nigricans, and virilization in females) had any significant growth-promoting effect (117) . Thus, these in vivo experiments involving IGF-I treatment in conditions characterized by severe insulin
IGF-I RESISTANCEresistance, similar to the in vitro data presented above, show variable findings insofar as concomitant IGF-I resistance is concerned. In summary, based mostly on studies performed in individuals with leprechaunism and severe genetically mediated insulin resistance, associated IGF-I resistance is only variably found. To date, no specific mutation of the IGF1R has been described in any patient with leprechaunism or in any human disease. Thus, it would appear that those patients with defects in both insulin or IGF-I action may possess a dual genetic abnormality in a common pathway beyond the convergence of the two pathways at the site of IRS-1 tyrosine phosphorylation. Alternatively, the inhibition of IGF-I signaling may be acquired secondary to the presence of abnormal insulin receptors. For example, it has been suggested that mutant insulin receptors form hybrid oligomers with wildtype IGF1Rs, and, thus, interfere with normal IGF-I signaling (118) . Another possibility is that mutant insulin receptors and wild-type IGF1Rs may compete for common substrates, such as IRS-1, or such substrates may be desensitized by chronic activation of mutant insulin receptors (111) . Nevertheless, it remains unclear as to why some patients with leprechaunism maintain normal IGF1R-mediated functions whereas others do not.
C. Deletions of the distal arm of chromosome 15
There have been 10 cases of patients described in the literature with deletions of the distal long arm of chromosome 15 (119 -125) , as well as 33 patients with ring chromosome 15 which often results in terminal 15q deletions (126 -135) . The majority of these patients had intrauterine growth retardation (IUGR) and postnatal growth failure in addition to other developmental abnormalities. Several genes have been mapped to 15q, including FES (feline sarcoma virus oncogene), FUR (furin membrane-associated receptor protein), CD13 antigen, CTSH (cathepsin H), and the IGF1R. The IGF1R gene has been assigned to 15q26.3. It has been proposed that absence of one copy of the IGF1R gene plays a role in the growth deficiency present in these syndromes. The patients that had deletions spanning the IGF1R gene had other clinical features in common. All had some craniofacial abnormalities, including microcephaly, triangular facies, hypertelorism, high-arched palate, abnormal ears, and micrognathia. All of these patients, except one of the siblings reported by Kristoffersson et al. (120) , also had skeletal abnormalities including clinodactyly, proximal placement of digits, club feet, and scoliosis. Those that survived the neonatal period all had developmental delay and mental retardation.
Five of the 10 cases had pulmonary abnormalities and of these, three also had renal abnormalities. The patient of Clark et al. (123) had lung hypoplasia and cystic renal dysplasia. The patient of Roback et al. (121) had lung hypoplasia and small kidneys. The siblings described by Kristoffersson et al. (120) both had lung hypoplasia and diaphragmatic hernias and also had cystic kidneys. The infant described by Siebler et al. (122) had lung hypoplasia and a diaphragmatic hernia.
Data on serum hormone levels in these patients are limited. Lack of one copy of the IGF1R gene might be expected to cause primary IGF-I resistance through a quantitative deficiency of the receptor. With end-organ insensitivity, negative feedback by IGF-I on the pituitary gland would be ineffective, resulting in elevated GH levels and, subsequently, elevated IGF-I levels. The patient of Roback et al (121) had a reportedly normal IGF-I level, but GH levels were not mentioned. The 12.3-yr-old female patient of Siebler et al. (122) had the most comprehensive evaluation. At 10.4 yr of age, her bone age was 7.5 yr. Her basal plasma GH level was normal and showed a normal response to glucagon stimulation. It is not clear whether serial basal GH levels were obtained. Multiple IGF-I levels were essentially normal except for a single elevated measurement of 340 g/liter at 2 yr of age (normal 11-206 g/liter). The girl was treated with three courses of hGH lasting 1-2 yr each. In the first two courses, there appeared to be an initial, but unsustained, increase in height velocity. Although the patient was clinically somewhat resistant to GH, the basal IGF-I and GH levels were not thought to be consistent with IGF-I resistance.
The two cases of Siebler et al. (122) , with confirmed lack of one copy of the IGF1R gene, had further studies of receptor expression and function in cultured fibroblast cell lines. Solution hybridization/nuclease protection assay results showed that the level of IGF1R mRNA was approximately 50% of that in control fibroblasts. Binding of [
125 I]IGF-I to placental tissue obtained from one case was normal. However, the investigators showed reduced ligand binding to IGF1R on cultured fibroblasts from both patients. Although they were unable to distinguish decreased receptor number from decreased binding affinity, the authors felt that, in light of the decreased IGF1R mRNA levels, the former etiology was more likely. They also studied responsiveness to IGF-I by quantification of IGF-I-stimulated [␣-1- 14 C]methyl-AIB uptake and [methyl-
3 H]thymidine incorporation by the patients' cultured fibroblasts. In these experiments, they were 636 JAIN ET AL. Vol. 19, No. 5 able to demonstrate that the maximal response to IGF-I was significantly decreased, compared with controls, in fibroblasts from one of the two patients when expressed as fold response over the basal value. However, when the data were expressed as net stimulation (maximal response minus basal), there was no significant decrease compared with controls. As the studies could not provide conclusive evidence for impaired biological responsiveness to IGF-I, the results suggest that growth retardation in these patients is not related to missing one copy of the IGF1R gene. The authors warn, however, that extrapolation of the cultured fibroblast data to other organ systems in situ may be inaccurate. It is possible that in certain tissues, IGF1R number is more tightly coupled to biological response. In such situations, decreased IGF1R number would result in IGF-I resistance with impaired growth response to IGF-I.
Ring chromosome 15.
The patients with ring chromosome 15 generally have deletions of 15q26.2 or 15q26.3 bands, although other terminal bands may be involved, as well as deletions of the distal short arm of chromosome 15 (126, 127) . In all 33 cases in the literature, there was postnatal growth failure (127) (128) (129) (130) (131) . In 14 of the 17 cases reviewed by Butler et al. (127) , birth length was below the fifth percentile. Phenotypic abnormalities included microcephaly (88%), mental retardation (95%), triangular facies (42%), hypertelorism (46%), brachydactyly (44%), various cardiac abnormalities (30%), cryptorchidism (30%), fifth finger clinodactyly (26%), and talipes equinovarus (15%). The absence of one copy of the IGF1R gene was documented in three of five patients described by Francke et al. (132) and Peoples et al. (128) . Those three who were hemizygous had severe growth failure, whereas those who had both copies of the IGF1R gene had only mild growth failure. Baba et al. (133) cited a case with one missing copy of the IGF1R gene. That child's height at 4 yr of age was Ϫ5.8 sd. Tamura et al. (134) reported an 11-yr-old girl with ring chromosome 15, pre-and postnatal growth failure, and deletion of one copy of the IGF1R gene.
Normal serum GH and IGF-I levels have been reported by several investigators although none specified whether frequent basal sampling was obtained (126, 127, (133) (134) (135) . Nuutinen et al. (136) described a child who did not have deletion of the IGF1R gene and whose IGF-I levels were subnormal. Although basal GH levels were not reported, the authors indicated a normal GH peak in response to clonidine stimulation (35.6 ng/ml), but a poor response to insulin-induced hypoglycemia (5.3 ng/ml). This child responded to GH therapy with sustained acceleration of growth and increase of IGF-I levels into the normal range. There are no published reports of GH treatment of any patient with ring chromosome 15 with deletion of the IGF1R gene. Neither have there been any studies on IGF1R expression or function.
In summary, some patients with ring chromosome 15 or deletions of the long arm of chromosome 15 have loss of one copy of the IGF1R gene. Although this may be associated with decreased IGF-I binding to its receptor, the exact mechanism has not been elucidated. Serum GH and IGF-I levels were not consistent with the pattern predicted for IGF-I resistance. Furthermore, there is, as yet, no evidence for altered tissue responsiveness to IGF-I which, if present, would represent a genetically regulated form of IGF-I resistance. Thus, there is no definitive evidence that lack of one copy of the IGF1R plays a causative role in the pre-and postnatal growth failure present in the majority of these patients.
D. Rare examples of "idiopathic" short stature associated with elevated circulating levels of IGF-I
The mouse "knockout" studies showed that isolated IGF-I deficiency caused IUGR and postnatal growth failure with variable survival. In humans with idiopathic short stature, there has only been one case described of a child with IUGR, short stature, dysmorphic features, mental retardation, and homozygosity for partial deletion of the IGF-I gene (137) . In contrast, mouse "knockout" studies showed that the interaction between IGF-I and the IGF1R is critical for normal prenatal growth and development. If this finding is applicable to humans, one would expect that congenital abnormalities causing primary IGF-I resistance would be exceedingly rare. Indeed, there have been only a handful of patients described in the literature who presented with "idiopathic" short stature and elevated IGF-I levels.
Lanes et al. (138) described a boy with IUGR and short stature. At 11 2/12 yr of age, his height was below Ϫ5 sd, and he had a 4-yr bone age delay. He had no dysmorphic features and no evidence of hypoglycemia. Basal 24-h integrated GH concentration was normal, as were insulin-argininestimulated GH levels. Basal IGF-I values were elevated to 3-5 times normal values and did not increase with 5 days of GH therapy. The patient's serum had normal IGF-I bioactivity, ruling out the presence of inhibitors or IGFBP abnormalities. The authors concluded that the findings were most consistent with an IGF1R or postreceptor defect. The lack of suppression of GH levels was attributed to ineffective negative feedback by IGF-I due to central IGF-I resistance. Momoi et al. (139) reported the case of a girl with IUGR and less severe postnatal growth failure than the patient described by Lanes et al. Her height tracked at Ϫ3 sd throughout childhood. She started menarche at 13 8/12 yr of age, but she had a final adult height of 134 cm (ϳϪ5 sd). She had some unusual dysmorphic features, including malar hypoplasia, thin and stiff hair, blue sclerae, and upslanting palpebral fissures. She had no episodes of hypoglycemia. Her basal GH levels were normal, as were her stimulated levels after a variety of stimuli, including insulin, l-dopa, glucagon, and arginine. Basal IGF-I levels were approximately 2-fold elevated above normal. The patient's serum had normal IGF-I bioactivity as measured by IGF-I-stimulated uptake of ) felt the fibroblast data could not be generalized to other organ systems. They suggested that tissue-specific unresponsiveness could be present. Bierich et al. (141) published the case of a young girl with IUGR and profound postnatal growth failure. She grew only 11 cm in the first year of life. Her dentition was delayed and she had a chubby face with a well developed skull, small snub nose, receded chin, and a relatively obese trunk. During her second year of life, she was noted to have several episodes of early-morning drowsiness due to hypoglycemia. The frequency of these episodes declined with the addition of a midnight meal. The girl's basal GH levels were elevated to 3-to 6-fold above normal and her basal IGF-I levels were elevated 6-fold. Her GH stimulation profile in response to arginine was abnormal with a small and delayed rise at 90 min. Her IGF-I level did not rise with GH stimulation. The patient's serum had normal IGF-I bioactivity. However, there was a 50% diminution of the specific binding of IGF-I to the patient's skin fibroblasts. The authors concluded that these findings were consistent with a genetically mediated defect of the IGF1R, although they did not study in vitro IGF-I action.
Heath-Monnig et al. investigated IGF-I responsiveness of fibroblasts from 11 normal control subjects and 9 patients with short stature, 5 of whom had normal GH concentrations and normal or increased IGF-I levels (140) . One patient was found to have decreased [
3 H]␣-AIB uptake. The general shape of her response curve was normal, and the eventual degree of stimulation was similar to that of normal fibroblasts, but the ED 50 was 3.3 times that of the mean of normal fibroblasts. Interestingly, the patient's mother's fibroblasts also had decreased sensitivity to IGF-I. The proband had IUGR and significant, but not profound, short stature; her height was approximately Ϫ3.5 sd at 9 3/12 yr of age. Binding studies indicated normal affinity and number of IGF1R. Tollefsen et al. (142) later studied the responsiveness of the patient's fibroblasts to [Q 3 , A 4 , Y 15 , L 10 ]IGF-I, an IGF-I variant that has 600-fold reduced affinity for serum IGFBPs, and which is, thus, less likely to have its action modulated by endogenous IGFBPs (140, 142) . In response to the variant IGF-I, the patient's fibroblasts had a normal ED 50 of [ 3 H]␣-AIB uptake, eliminating the possibility of a defect of the IGF1R. Ligand blot analysis showed that the patient's fibroblasts secreted a significantly greater amount of several IGFBPs. The cells had a 10-fold increase in the amount of cell surface M r 32,000 binding protein. Based on these findings, the authors concluded that abnormal production and/or cell association of IGFBPs caused resistance to IGF-I action in this patient.
In summary, cases of congenital IGF-I resistance associated with postnatal growth failure beginning immediately in the neonatal period and elevated IGF-I levels are extremely rare. Only one patient had documented tissue IGF-I resistance. The failure to demonstrate IGF-I resistance in two other patients with clinical and hormonal profiles consistent with this diagnosis may be attributable to the fact that only fibroblasts were studied. These patients may have tissue mosaicism, which allowed them to survive and have limited clinical manifestations. There has also been one patient described with congenital, secondary IGF-I resistance due to altered IGF-I bioavailability as a result of a genetically directed abnormality of IGFBP.
VI. Conditions Associated with Acquired IGF-I Resistance in Humans
A. HIV-1 infection
Growth retardation, specifically failure-to-thrive (FTT), is a common feature of pediatric HIV-1 infection, irrespective of whether it is acquired by vertical transmission or by transfusion, and is one criterion used to define Centers for Disease Control (CDC) stage P2 (143) . The mechanism for FTT in pediatric HIV-1 infection is unknown, although it has been linked to associated anorexia, malnutrition, diarrhea, and opportunistic infection (144 -146) . Although resistance to GH, IGF-I, and other growth factors has been previously suggested as a potential cause for growth failure in children with pediatric HIV-1 infection (145, 146) , most previous studies have failed to show any relationship between serum hormone levels and poor growth. Both normal and low serum levels of IGF-I have been described in HIV-1-infected children and adults, with lower levels reported in children with FTT; GH levels have generally been reported as normal in patients with HIV-1 infection independent of their clinical status (147) (148) (149) (150) . Additionally, low levels of IGFBP-3 and acid-labile subunit, two members of the circulating ternary complex, with IGF-I being the third, have been reported to be low in poorly growing children with HIV-1 infection; these same children tend to have enhanced IGFBP-3 proteolysis, as seen in other hypercatabolic states (151) .
To assess the roles of hormone deficiency and hormone resistance in the development of poor growth in HIV-1-infected children, we studied six asymptomatic children (stage P1) [height sd score (SDS) ϭ 0.01 Ϯ 1.0 (mean Ϯ sd)]; 10 symptomatic, but not acutely ill children (stage P2) (height SDS ϭ Ϫ2.0 Ϯ 1.0); and six short, normal children (height SDS ϭ Ϫ2.4 Ϯ 1.2) matched in height to the stage P2 group (152) . Mean weight-height SDS ratios were similar in all three groups, suggesting that nutritional status did not differ between groups. There were no significant differences between groups with respect to mean plasma levels of IGF-I, thyroid hormones, TSH, and cortisol. As an index of hormone sensitivity, we quantified in vitro colony formation of erythroid progenitor cells (EPC), isolated from peripheral blood of study subjects, in response to IGF-I, GH, and insulin. Mean overall EPC responsiveness of P2 patients to IGF-I was significantly reduced compared with that of both P1 subjects and controls (Fig. 10A) . Mean overall EPC responsiveness of P2 subjects to GH was moderately reduced compared with that of both P1 subjects and controls (Fig. 10B) . EPC responsiveness to insulin was also significantly reduced in P2 subjects compared with both P1 subjects and controls at various insulin concentrations (Fig. 10C) . Thus, we found that more severe HIV-1 infection in children is associated with in vitro resistance to the growth-promoting actions of IGF-I, GH, and insulin, which is unrelated to the presence of malnutrition or overwhelming illness. This presumably acquired resistance 638 JAIN ET AL. Vol. 19, No. 5 to IGF-I and GH could contribute to the poor in vivo growth seen in symptomatic HIV-1-infected children.
The mechanism by which IGF-I resistance develops in children with symptomatic HIV-1 infection could be related to the increased production of cytokines that occurs in patients with acquired immunodeficiency syndrome (AIDS). Specifically, tumor necrosis factor (TNF) production is increased in some AIDS patients, particularly in the setting of opportunistic infections, progressive encephalopathy, and wasting (153) . While IGF-I has been shown to promote human adult and embryonic erythropoiesis, TNF inhibits in vitro erythroid colony formation (154) . Although IGF-I promotes in vitro cartilage matrix formation (proteoglycan synthesis) equally in the presence or absence of TNF␣ (155), transient in vitro exposure of human myoblasts to TNF␣ significantly inhibits IGF-I-stimulated protein synthesis (156) . Thus, the in vitro cellular resistance to IGF-I demonstrated in our P2 subjects may be linked to exaggerated production of TNF and/or other cytokines.
Furthermore, if the mechanism for the observed GH and IGF-I resistance in children with symptomatic HIV-1 infection involves the IGF1R, one might also expect there to be resistance to supraphysiological concentrations of insulin, the action of which is usually mediated through the IGF1R (67). Since we observed a statistically significant reduction in responsiveness to only certain physiological concentrations of insulin, it is unlikely that a defect in the IGF1R-effector mechanism develops in these patients. Alternatively, the presence of circulating inhibitors of IGF-I action could explain resistance to GH and IGF-I without resistance to supraphysiological concentrations of insulin, one such mechanism being increased production of IGFBPs (157) .
Further evidence supporting the presence of acquired IGF-I resistance in patients with HIV-1 infection and clinical wasting is based on studies of their responsiveness to in vivo GH and/or IGF-I administration (158) . The phenotype of the wasting associated with HIV-1 infection is characterized by a progressive loss of weight in the form of both lean body mass and fat mass (159) ; early attempts at treatment with nutritional and pharmacological therapies generally improved weight through repletion of fat mass (160, 161) . Loss of lean body mass is also a feature of both childhood-and adult-onset GH deficiency (162) and of genetic GH resistance (Laron dwarfism) (163) , prompting experimentation with GH in the setting of AIDS wasting. Although initial studies of short-term (1 week to 3 months) administration of human GH to adult HIV-1-infected men with associated wasting showed significantly increased protein anabolism, as manifested by an increase in lean body mass and weight and a concomitant decrease in fat mass, the doses of GH that were necessary to evoke such responses were clearly pharmacological (164 -166 ). An additional 2-week study of GH adminstration at pharmacological doses to HIV-1-infected adults showed no significant increase in the rate of protein synthesis in vastus lateralis muscle (167) . These results suggested a partial resistance to GH, or perhaps to GH and IGF-I (as the mediator of GH action) or to IGF-I alone, which could be overcome by increasing the dose of exogenous GH. Subsequent studies to evaluate the anabolic effects of recombinant IGF-I administration to cachectic adult patients with HIV- 1   FIG. 10 . EPC responsiveness to IGF-I, GH, and insulin in HIV-1-infected and short, normal children. The unstimulated number of erythroid progenitor cell colonies (referred to, on the ordinate, as colonies) formed in incubation mixtures without added growth factor is defined as 100%. The abscissa represents the concentrations of added growth factor (ng/ml). The data are presented as the mean Ϯ SE. P1, Asymptomatic HIV-1-infected children. P2, symptomatic HIV-1-infected children [specific P-staging criteria based on standardized CDC criteria (143) ]. Short controls, Short, endocrinologically normal children. A, IGF-I (upper panel). P2 subjects had significantly reduced mean EPC colony formation in response to direct IGF-I stimulation [P ϭ 0.004 vs. P1 subjects and P ϭ 0.04 vs. controls (by ANOVA)]; there was no statistically significant difference between P1 subjects and controls. B, GH (middle panel). P2 subjects had significantly reduced mean EPC responsiveness to GH compared with P1 subjects (P ϭ 0.05 by ANOVA). There was a similar trend toward decreased responsiveness to GH in P2 subjects compared with controls (P ϭ 0.06 by ANOVA); there was no statistically significant difference between P1 subjects and controls. C, Insulin (lower panel). Although there were no overall differences in EPC colony formation in response to insulin between the three groups by ANOVA, there were significant individual differences between P2 and P1 subjects at an insulin concentration of 8 ng/ml (P ϭ 0.02) and between P2 subjects and controls at insulin concentrations of 8 and 9 ng/ml (P ϭ 0.002 and P ϭ 0.001, respectively (169, 170) . In summary, in vitro and in vivo evidence is provided consistent with the presence of acquired and partial resistance to both GH and IGF-I in symptomatic adults and children with HIV-1 infection. Such resistance may play a role in the growth disturbances seen in symptomatic children and in the wasting syndrome seen in both children and adults with AIDS.
B. Chronic renal insufficiency
Growth retardation in children with chronic renal insufficiency (CRI) has been linked to multiple metabolic and hormonal abnormalities. When CRI occurs in the first few months of life, infants demonstrate a major growth loss during the first 6 months of life, possibly due to the high metabolic requirements that are not met by nutritional intake (171, 172) . Subsequently, institution of appropriate nutritional therapy, correction of metabolic acidosis, and treatment of renal osteodystrophy promote reversal of the catabolic state with some improvement of linear growth and even some catch-up growth in cases of moderate renal insufficiency (173) . In CRI, a normal height velocity is rarely achieved (174, 175) . Abnormal pubertal growth has been well described in adolescents with CRI and includes a delay in onset of the pubertal growth spurt, a lower minimal prespurt height velocity, and an attenuation of the peak height velocity (176) . The impact on final height clearly depends on the age of onset and severity of the renal disease. Those affected from birth enter puberty with heights greater than 2 sds below the mean and frequently have adult heights greater than 3 sds below the mean.
Perturbations of the GH/IGF-I system have been implicated in the etiology of poor growth in CRI. It has long been known that this growth failure occurs in the setting of elevated serum GH levels (2, 177, 178) . As the kidneys contribute significantly to the degradation of GH, the serum half-life of GH is increased in CRI (179) . Furthermore, there is evidence for increased pulsatile release of GH in children with renal disease (180) . Finally, levels of serum GHBP, the soluble form of the GH receptor, are reduced in CRI with the lowest levels occurring in children with end-stage renal disease (181) . After hemodialysis, patients have decreased GH concentrations compared with predialysis, presumably due to the removal of free GH.
Most investigators have described normal serum IGF-I levels in patients with CRI (2). Malnutrition, which may be present in a subgroup of patients with CRI, is known to be associated with reduced serum IGF-I levels and bioactivity (see Section IV). Despite the normal serum IGF-I levels in CRI, it has been shown that there is reduced hepatic IGF-I gene expression in experimental uremia (182) . This may be secondary to reduced density of GH receptors in target organs in the uremic state. Indeed, reduced GH receptor numbers have been shown in uremic rats (183) and are thought to be present in humans with CRI, the majority of whom have GHBP levels below the mean for age and gender (181) . The limited data available regarding IGF-II levels have shown elevations in patients with CRI (184) . A variety of IGFBPs are present in higher concentrations in CRI (2). IGFBP-3 levels are elevated as measured by RIA. However, as IGFBP-3 is subject to specific protease degradation into lower molecular weight fragments that are cross-reactive on RIA, the total intact IGFBP-3 levels are probably not increased. IGFBP-1 and -2 concentrations are truly increased and IGFBP-4 levels are slightly increased.
Several of the above observations indicate the presence of GH resistance in patients with CRI. Growth failure and reduced hepatic IGF-I mRNA levels in the face of normal or elevated GH concentrations fit the paradigm of GH insensitivity. The apparent insensitivity can be overcome as demonstrated by the dramatic short-term height increments in patients with CRI treated with GH (185) . The mechanism of resistance may be reduced GH-receptor expression, although this has not been demonstrated in tissues other than the liver. GH resistance could also be secondary to IGF-I resistance, for which there is increasing evidence (2) .
IGF-I resistance in CRI was first identified when it was observed that the sera of hemodialysis patients had decreased sulfate-incorporation activity compared with that of normal individuals. There was partial restoration of this activity after hemodialysis, suggesting the presence of removable inhibitors (186) . The low molecular weight binding protein IGFBP-1 (formerly known as IGFBP-25) has been shown to be elevated in CRI (187) . An elegant set of experiments conducted by Dong et al. (188) provided evidence that there may also be a functional IGF1R defect causing IGF-I resistance. Uremic nonacidotic rats were found to have decreased protein catabolism and increased protein synthesis when treated with IGF-I, although the response at each dose was less than that of normal controls. These uremic animals had decreased skeletal muscle IGF-I and IGF-I mRNA levels, but elevated IGF1R mRNA levels. The investigators confirmed elevated IGF1R numbers with normal ligand affinity. However, autophosphorylation and IGF-I substrate phosphorylation were decreased.
In summary, there is reasonable evidence that patients with CRI have both GH resistance and IGF-I resistance. It is not clear whether the GH resistance is primary, possibly due to decreased GH-receptor expression, or secondary to IGF-I resistance acquired as a result of CRI. IGF-I resistance could be due to inhibition of IGF-I bioactivity by elevated IGFBP-1 levels or to a postreceptor defect involving the IGF1R.
C. Mauriac syndrome
Mauriac syndrome (MS) was first described in the 1930s as the triad of poorly controlled diabetes mellitus, dwarfism, and hepatomegaly secondary to excessive hepatic glycogen deposition (189) . Now, in an era of early recognition of insulin-dependent diabetes mellitus (IDDM) and its complications, and implementation of tighter blood sugar control, MS has become extremely rare. Although it is well recognized that uncontrolled IDDM impairs growth, the correlation between glycemic control and final adult height is poor.
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JAIN ET AL. Vol. 19, No. 5 In a study of twins discordant for diabetes, the affected twin was shorter if the condition developed before the onset of puberty (190) . Similarly, in a 3-yr study, Herber and Dunsmore (191) showed that the younger the child is at the time of diagnosis of diabetes, the smaller the loss in height SDS. In that study, there was no correlation between hemoglobin A 1 levels and either short-or long-term growth. Diabetic children with normal height and normal growth velocity while under relatively poor control experienced a sharply increased growth velocity during intensive treatment (192) . Despite all the evidence that children with IDDM and poor control have altered linear growth, the vast majority of these patients achieve a normal final height. Patients with IDDM have elevated GH levels (basal and stimulated) and concomitantly low IGF-I levels (basal and stimulated), which are related to glycemic control (193) (194) (195) (196) (197) . Adults with IDDM have 2-to 3.5-fold higher integrated 24-h GH concentrations with significantly increased amplitudes of GH release than do age-and sex-matched control subjects. Those diabetic patients who are younger than 20 yr of age have significantly higher integrated GH concentrations than do older patients. Although the data are somewhat conflicting, there is a preponderance of evidence that the degree of abnormality of GH and IGF-I levels improves with good blood glucose control. Lanes et al. compared two groups of children with IDDM, one with hemoglobin A 1c values ranging from 7.9 to 11.2% and the other with hemoglobin A 1c values ranging from 12.5 to 15.6% (195) . They found that, though the two groups had similar basal GH concentrations, the group with poorer glycemic control had a significantly higher mean GH level after stimulation with clonidine. In contrast, the group with poorer control had little or no increase in IGF-I levels in response to administered GH. Maes et al. (198) investigated this situation in diabetic rats. They found that affinity constants and liver GH-binding capacities were similar in diabetic and control rats. The maximal IGF-I response in diabetic rats, however, was significantly less than that in contol rats, suggesting a postreceptor defect causing GH resistance. Amiel et al. (196) showed that changing from conventional to intensified insulin therapy resulted in an increase in previously low IGF-I levels and a fall in the mean 24-h GH levels within 1 week. Likewise, Bereket et al. (199) found that institution of insulin treatment in children newly diagnosed with IDDM initially had an increase in free IGF-I levels, followed by near-normalization of total IGF-I levels in 1 month. IGF-1I levels are generally normal (197) . IGFBP concentrations are altered in IDDM. As IGFBP-1 levels are down-regulated by insulin, children with insulinopenia have elevated circulating levels of this binding protein, which inhibits IGF-I action (200, 201) . IGFBP-2 and -4 concentrations are also increased, but it is not known whether this is a direct effect of low insulin. IGFBP-3 levels, which are GHdependent, are reduced (200, 201) . The combination of low IGF-I and elevated IGFBP-1 is thought to result in decreased IGF-I bioavailability.
Very few patients with MS have been available for extensive study of their GH-IGF-I axis. Mauras et al. compared the profiles of two patients with MS to five normally growing patients with IDDM (202) . They found that mean GH concentrations were elevated compared with normal. The 12-h GH concentrations, pulse amplitude, and pulse frequency were similar between the two groups and did not change with acute normalization of the serum glucose overnight in the MS patients. GH responses to GHRF did not differ between the groups. GHBP relative binding was also the same and was similar to levels in nondiabetic sera. IGF-I concentrations were normal. Western blot analysis of IGFBPs did not detect any consistent difference in band patterns between MS patients, diabetic patients with normal growth, and normal controls. One of the patients with MS was treated for 1 yr with GH therapy, but without a meaningful increase in growth velocity. There was also no increase in IGF-I levels during that time.
The mechanisms causing growth failure in MS are not well understood. The finding of elevated GH concentrations in the setting of poor linear growth suggests GH resistance. The lack of growth acceleration in the MS patient treated with GH supports the existence of GH resistance, which may be primary or secondary to IGF-I resistance. Normal GHBP levels are indirect evidence of normal GH receptor expression, and rat models of IDDM indicated normal GH-receptor binding capacity. The normal or low IGF-I concentrations point toward low GH bioactivity. There is also some evidence for acquired IGF-I resistance in other models of diabetes mellitus. Sera from patients with poor glycemic control have reduced IGF-I activity at the cartilage level that improves with better metabolic control (203) . Other studies have described IGF-I inhibitors in the sera of diabetic rats (204) . Rats made hypoinsulinemic by streptozotocin or citrate buffer administration had markedly increased serum IGF-I binding activity, which fell toward normal during insulin therapy (205) . This serum-binding activity was attributed to increased levels of a 32,000 M r IGFBP that is immunologically related to human IGFBP-1. It is possible that, in the case of MS, IGFBPs less predominant than the ones evaluated by Western blot bind IGF-I and inhibit its biological activity. One investigator found antibodies to the IGF1R in a patient with IDDM (206) . This patient, however, had elevated IGF-I levels.
In summary, MS is a rare condition of extreme growth failure in the setting of IDDM and hypoinsulinemia, with elevated GH concentrations and low or normal IGF-I concentrations. These patients have an acquired GH resistance, possibly secondary to underlying reversible IGF-I resistance. The presence of IGF-I resistance is suggested by reduced responsiveness to GH and may be due to decreased bioavailability of IGF-I. It is also possible that there is a reversible receptor or postreceptor defect.
VII. Conclusions
IGF-I resistance in children, characterized by normal or elevated IGF-I levels and growth failure, may be present in a variety of clinical conditions. Congenital genetically regulated IGF-I resistance appears to be exceedingly rare. There are no reported cases of homozygous IGF1R gene deletions, suggesting that this genotype is highly lethal. Heterozygosity for IGF1R gene deletion, however, is well described, but the accompanying growth failure is not definitively attributable to the lack of one copy of the IGF1R gene. In cases of presumed congenital IGF-I resistance, tissue insensitivity has not always been proven, suggesting that some patients may have somatic mosaicism for receptor or postreceptor defects. In one case, a congenital binding protein abnormality was implicated in causing secondary IGF-I resistance. Disease states such as IDDM, severe insulin resistance, CRI, and HIV infection may cause acquired IGF-I resistance through decreasing IGF-I bioavailability or affecting cellular responsiveness by altering second messenger systems. Finally, the IGF-I resistance in African Efe Pygmies may represent a genetic adaptation that confers a selective advantage. Such an adaptation would imply the presence of compensatory mechanisms to allow an otherwise normal physiology and phenotype.
